A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
Terminated · Phase 3 · NCT05582395
Conditions: Cardiomyopathy, Hypertrophic
At a glance
- Research payments reported, 2025
- $502
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 580
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Mavacamten (drug), Placebo (other)
- Dates
- Started 2022-12-14; completion 2025-10-20
- Results posted
- Yes
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
From ClinicalTrials.gov, last updated 2026-09-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $502 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.